Schedule III marijuana and the harm to the American family
The recent reclassification of marijuana from Schedule I to Schedule III has raised concerns about its impact on American families. Critics argue that this move, driven by financial interests, overlooks the significant mental health issues associated with marijuana use. The article calls for stricter regulations and highlights the need for a balanced approach to marijuana legislation.
- ▪The federal government has moved marijuana products from Schedule I to Schedule III under the Controlled Substances Act.
- ▪Cannabis use disorder affects 20.6 million people over the age of 12, with significant mental health impacts on those under 25.
- ▪The reclassification allows marijuana corporations to claim over $2 billion in annual federal tax breaks.
Opening excerpt (first ~120 words) tap to expand
Recently, our federal agencies, under the prompting of the Trump administration, moved marijuana products regulated by a state medical marijuana license, and FDA-approved products containing marijuana, from Schedule I to Schedule III of the Controlled Substances Act. Public hearings, which are supposed to occur before such a move, will be held sometime in the future. The public-facing reason for this move was to research cannabidiol and marijuana for medicinal purposes. However, CBD has been legally available since the 2018 federal Farm Bill authorized hemp production, and we did not need to reschedule marijuana to study it.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Washington Examiner.
Discussion
0 commentsMore from Washington Examiner
